- Home
- ENVB vs CHRO Comparison
ENVB vs CHRO Comparison
Compare ENVB & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- CHRO
- Stock Information
- Founded
- ENVB 1994
- CHRO 2002
- Country
- ENVB United States
- CHRO United States
- Employees
- ENVB N/A
- CHRO N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- ENVB Health Care
- CHRO
- Exchange
- ENVB Nasdaq
- CHRO Nasdaq
- Market Cap
- ENVB 4.1M
- CHRO 3.8M
- IPO Year
- ENVB N/A
- CHRO 2024
- Fundamental
- Price
- ENVB $0.35
- CHRO $1.90
- Analyst Decision
- ENVB Strong Buy
- CHRO Strong Buy
- Analyst Count
- ENVB 1
- CHRO 1
- Target Price
- ENVB $10.00
- CHRO N/A
- AVG Volume (30 Days)
- ENVB 1.0M
- CHRO 855.2K
- Earning Date
- ENVB 11-14-2024
- CHRO 02-20-2025
- Dividend Yield
- ENVB N/A
- CHRO N/A
- EPS Growth
- ENVB N/A
- CHRO N/A
- EPS
- ENVB N/A
- CHRO N/A
- Revenue
- ENVB N/A
- CHRO N/A
- Revenue This Year
- ENVB N/A
- CHRO N/A
- Revenue Next Year
- ENVB N/A
- CHRO N/A
- P/E Ratio
- ENVB N/A
- CHRO N/A
- Revenue Growth
- ENVB N/A
- CHRO N/A
- 52 Week Low
- ENVB $0.30
- CHRO $0.45
- 52 Week High
- ENVB $2.92
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- ENVB 46.61
- CHRO 86.63
- Support Level
- ENVB $0.35
- CHRO $0.81
- Resistance Level
- ENVB $0.39
- CHRO $1.10
- Average True Range (ATR)
- ENVB 0.05
- CHRO 0.26
- MACD
- ENVB -0.00
- CHRO 0.08
- Stochastic Oscillator
- ENVB 19.56
- CHRO 70.64
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.